[go: up one dir, main page]

PE20140576A1 - Vacunas bovinas y metodos - Google Patents

Vacunas bovinas y metodos

Info

Publication number
PE20140576A1
PE20140576A1 PE2013002768A PE2013002768A PE20140576A1 PE 20140576 A1 PE20140576 A1 PE 20140576A1 PE 2013002768 A PE2013002768 A PE 2013002768A PE 2013002768 A PE2013002768 A PE 2013002768A PE 20140576 A1 PE20140576 A1 PE 20140576A1
Authority
PE
Peru
Prior art keywords
hardjo
bovis
inactivated
immune response
composition
Prior art date
Application number
PE2013002768A
Other languages
English (en)
Inventor
Eric Springer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20140576A1 publication Critical patent/PE20140576A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE: A) LEPTOSPIRA BORGPETERSENII INACTIVADO SEROVARIANTE HARDJO, TIPO HARDJO-BOVIS (L. HARDJO-BOVIS); B) COMPONENTES ADICIONALES TALES COMO LEPTOSPIRA INTERROGANS INACTIVADO, SEROVARIANTES CANICOLA, GRIPPOTYPHOSA, CAMPYLOBACTER FETUS INACTIVADO, ENTRE OTROS; Y C) ADYUVANTES. DICHA COMPOSICION ES UTIL PARA LA ESTIMULACION DE UNA RESPUESTA INMUNE EFICAZ CONTRA LEPTOSPIRA Y UNA RESPUESTA INMUNE ESPECIFICA PARA L. HARDJO-BOVIS. TAMBIEN SE REFIERE A UN METODO PARA ESTIMULAR DICHA RESPUESTA INMUNE EN ANIMALES BOVINOS QUE COMPRENDE ADMINISTRAR A LOS ANIMALES ENTRE 4 A 26 SEMANAS DE EDAD DICHA COMPOSICION; Y UNA SEGUNDA ADMINISTRACION DE UNA CANTIDAD INMUNOGENICA DE L. HARDJO-BOVIS INACTIVADO 8 SEMANAS DESPUES; EN DONDE DICHO METODO ES UTIL EN LA PREVENCION DE LEPTOSPIROSIS CRONICA
PE2013002768A 2011-06-10 2012-06-08 Vacunas bovinas y metodos PE20140576A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161495591P 2011-06-10 2011-06-10

Publications (1)

Publication Number Publication Date
PE20140576A1 true PE20140576A1 (es) 2014-05-24

Family

ID=47296754

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002768A PE20140576A1 (es) 2011-06-10 2012-06-08 Vacunas bovinas y metodos

Country Status (6)

Country Link
US (1) US9364527B2 (es)
CA (1) CA2836805C (es)
CO (1) CO6870003A2 (es)
MX (1) MX345704B (es)
PE (1) PE20140576A1 (es)
WO (1) WO2012170753A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP6990176B2 (ja) 2015-10-05 2022-02-03 モデルナティエックス インコーポレイテッド メッセンジャーリボ核酸薬物の治療投与のための方法
DK3407734T3 (da) 2016-01-25 2023-05-01 Signify North America Corp Biosikkerhedssystem til en landbrugsbygning

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501213A (en) * 1998-12-22 2001-09-28 Pfizer Prod Inc Isolated leptospira membrane kinase, membrane permease, membrane mannosyltransferase and endoflagellin proteins for preventing leptospirosis
WO2004017990A1 (en) * 2002-08-26 2004-03-04 Pfizer Products Inc. Vaccine for respiratory and reproductive system infections in cattle
US7563449B2 (en) * 2003-04-21 2009-07-21 Pfizer Inc, Methods for reducing cattle reproductive diseases
UY29915A1 (es) * 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
CN104758929B (zh) 2008-06-27 2018-05-25 硕腾有限责任公司 新颖的佐剂组合物

Also Published As

Publication number Publication date
US20140105930A1 (en) 2014-04-17
MX345704B (es) 2017-02-10
CA2836805A1 (en) 2012-12-13
CA2836805C (en) 2023-03-07
US9364527B2 (en) 2016-06-14
MX2013014485A (es) 2014-03-21
CO6870003A2 (es) 2014-02-20
WO2012170753A3 (en) 2014-05-08
WO2012170753A2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
PE20140576A1 (es) Vacunas bovinas y metodos
MX2021001762A (es) Metodo y composicion para estimular la respuesta inmunitaria.
ECSP14013201A (es) Formulaciones parenterales de vacunas contra los norovirus
BR112012021805A2 (pt) dispositivo de eletroporação de pele tolerável e minimamente invasivo
PH12013502174B1 (en) Vaccine delivery method
MX2020009682A (es) Vacunas de nanoparticulas multivalentes contra la influenza.
BR112016007390A2 (pt) vacina de haemophilus parasuis sorotipo tipo quatro
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
BR112014001409A2 (pt) métodos e composições para vacinação contra staphylococcus aureus
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
NZ704204A (en) Method of providing protective immunity against heterologous leptospira strains
AR093424A1 (es) Vacunas atenuadas de mannheimia haemolytica y metodos para su elaboracion y uso
CL2022000086A1 (es) Vacunas contra ehrlichia y composiciones inmunogénicas
PH12012500383A1 (en) Heterlogous prime-boost immunization regimen against bluetongue virus
EP4509185A3 (en) Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans
UA127236U (uk) Вакцина проти лептоспірозу врх полівалентна (варіант bovis)
UA127237U (uk) Вакцина проти лептоспірозу свиней (варіант suis)
UA91615U (uk) Вакцина проти лептоспірозу тварин полівалентна (варіант equi)
CL2025001726A1 (es) Métodos de administración de vacunas a salmónidos
UY33780A (es) ?composiciones y métodos para vacunar ganado vacuno?.
UA132124U (uk) Вакцина проти лептоспірозу м'ясоїдних бівалентна
MX368742B (es) Metodo y composiciones para reducir los niveles sericos de triacilgliceridos en seres humanos con una lipasa fungica.

Legal Events

Date Code Title Description
FC Refusal